Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 1—January 2013
Research

Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales

Shamez N. LadhaniComments to Author , Mary P.E. Slack, Nick J. Andrews, Pauline A. Waight, Ray Borrow, and Elizabeth Miller
Author affiliations: Author affiliations: Health Protection Services Colindale, London, UK (S.N. Ladhani, M.P.E. Slack, N.J Andrews, P.A Waight, E. Miller); Health Protection Agency, Manchester, UK (R. Borrow)

Main Article

Table 3

Association between infecting pneumococcal serotype group and presence of comorbidity, England and Wales, September 4, 2006–March 31, 2010*

Serotype group Comorbidity, no./total (%) aOR† (95% CI) p value
All PCV7-IPD cases‡ 44/248 (17.7)
3 extra PCV10 serotypes (1, 5, 7F)
15/299 (5.0) §
0.24 (0.13–0.45) against PCV7
<0.001
3 extra PCV13 serotypes (3, 6A, 19A) 45/336 (13.4)§ 0.72 (0.46–1.13) against PCV7 0.15


3.58 (1.93–6.66) against PCV10‡
<0.001
11 extra PPV23 serotypes 39/186 (21.0) 1.23 (0.76–1.99) against PCV7 0.40
6.02 (3.16–11.5) against PCV10 <0.001


1.68 (1.04–2.71) against PCV13
0.033
Remaining non-PPV23 serotypes 38/138 (27.5) 1.76 (1.07–2.89) against PCV7 0.025
8.57 (4.46–16.5) against PCV10 <0.001
2.39 (1.46–3.93) against PCV13 0.001
1.42 (0.85–2.40) against PPV23 0.18

*aOR, adjusted odds ration; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent polysaccharide vaccine.
†Odds ratio adjusted for age, vaccination status, and time since PCV7 introduction by using a multinomial logistic regression with serotype group as the outcome.
‡Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
§Comorbidity was lower for each of the 3 extra PCV10 serotypes, 1 (7/129, 5.4%), 5 (1/17, 5.9%), and 7F (7/153, 4.6%), compared with the additional 3 serotypes in PCV13, 3 (13/98, 13.3%), 6A (12/47, 25.5%), and 19A (20/191, 10.5%).

Main Article

Page created: December 20, 2012
Page updated: December 20, 2012
Page reviewed: December 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external